Insider Selling: Moderna (NASDAQ:MRNA) President Sells $8,640,084.40 in Stock

Posted by Francis Steltz on Oct 16th, 2026

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) President Stephen Hoge sold 39,145 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $220.72, for a total value of $8,640,084.40. Following the sale, the president owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. This represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

On Wednesday, October 14th, Stephen Hoge sold 39,224 shares of Moderna stock. The stock was sold at an average price of $213.48, for a total value of $8,373,539.52.
On Monday, September 14th, Stephen Hoge sold 40,294 shares of Moderna stock. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22.
On Tuesday, September 15th, Stephen Hoge sold 40,281 shares of Moderna stock. The stock was sold at an average price of $146.07, for a total value of $5,883,845.67.

Moderna Trading Down 7.8%

Shares of NASDAQ:MRNA traded down $18.49 during trading on Friday, reaching $218.01. 21,331,755 shares of the stock were exchanged, compared to its average volume of 12,344,437. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $242.29. The firm has a market cap of $87.04 billion, a price-to-earnings ratio of -27.29 and a beta of 1.09. The firm’s 50-day moving average price is $153.48 and its 200 day moving average price is $89.98.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same quarter in the prior year, the company earned ($2.13) EPS. The company’s revenue was up 2.1% on a year-over-year basis. On average, sell-side analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Moderna

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Moderna during the 2nd quarter worth approximately $2,142,877,000. Theleme Partners LLP acquired a new position in shares of Moderna in the 2nd quarter valued at approximately $564,272,000. Wellington Management Group LLP boosted its stake in shares of Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after buying an additional 103,977 shares during the last quarter. First Trust Advisors LP boosted its stake in shares of Moderna by 59.3% during the 1st quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock valued at $121,549,000 after buying an additional 891,072 shares during the last quarter. Finally, Merck & Co. Inc. purchased a new position in shares of Moderna during the 2nd quarter valued at approximately $161,642,545. Institutional investors and hedge funds own 75.33% of the company’s stock.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Investor enthusiasm remains centered on Moderna’s upcoming personalized cancer-vaccine data, particularly melanoma results expected next week. The catalyst helped drive the recent rally and keeps the company’s oncology pipeline in focus. Moderna falls ahead of cancer vaccine data next week
Positive Sentiment: Moderna and Merck’s earlier cancer-vaccine progress continues to support optimism about the companies’ oncology strategy, although additional development work is still required. Merck and Moderna cancer vaccine strategy
Neutral Sentiment: Goldman Sachs raised its price target to $137 from $120 while retaining a Neutral rating. The increase acknowledges Moderna’s momentum, but the target remains well below the stock’s recent trading level. Goldman raises Moderna price target
Negative Sentiment: After gaining sharply on cancer-vaccine expectations, Moderna is experiencing profit-taking as investors reassess whether the rally has moved ahead of near-term fundamentals. Analysts have highlighted the company’s continuing losses, negative free cash flow, and valuation sensitivity to successful pipeline execution. Moderna stock sinks as Wall Street turns cautious
Negative Sentiment: The selloff is also affecting vaccine developers broadly, with Novavax under heavier pressure and other vaccine stocks weakening. This sector-wide risk reduction is adding to selling pressure on MRNA. Selloff hits vaccine makers

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on MRNA shares. JPMorgan Chase & Co. increased their price objective on shares of Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. Wolfe Research raised shares of Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, August 25th. Evercore lifted their target price on shares of Moderna from $50.00 to $80.00 in a report on Thursday, October 8th. CLSA upgraded shares of Moderna to an “outperform” rating in a report on Friday, August 28th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $130.00 price target on shares of Moderna in a research report on Wednesday, August 19th. Seven analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $101.45.

Get Our Latest Report on Moderna

Moderna Company Profile

(Get Free Report)

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.